8
|
Joensuu H, Rutkowski P, Nishida T, Steigen SE, Brabec P, Plank L, Nilsson B, Braconi C, Bordoni A, Magnusson MK, Sufliarsky J, Federico M, Jonasson JG, Hostein I, Bringuier PP, Emile JF. KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence. J Clin Oncol 2015; 33:634-42. [PMID: 25605837 DOI: 10.1200/jco.2014.57.4970] [Citation(s) in RCA: 109] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
PURPOSE Mutated KIT and platelet-derived growth factor alpha gene (PDGFRA) drive GI stromal tumor (GIST) oncogenesis, but the clinical significance of their single mutations is known incompletely. PATIENTS AND METHODS We identified 11 population-based series of patients with GIST through a literature search and pooled individual data from 3,067 patients treated with macroscopically complete tumor excision. Mutation analysis was done from 1,505 tumors. We analyzed associations between KIT and PDGFRA mutations and recurrence-free survival (RFS) in the subsets in which patients were treated with surgery alone. RESULTS We identified 301 different single mutations in KIT and 33 in PDGFRA. Patients with PDGFRA mutations had more favorable RFS than those with KIT mutations (hazard ratio, 0.34; P = .004). Only one of the 35 GISTs with KIT exon 11 duplication mutations recurred. Patients with deletions of only one codon of KIT exon 11 had better RFS than those with another deletion type, and some KIT exon 11 substitution mutations (Trp557Arg, Val559Ala, and Leu576Pro) were also associated with favorable RFS. Patients with an identical mutation had greatly variable outcomes depending on the standard prognostic factors, notably, mitotic count. Commonly used risk stratification schemes tended to overestimate the risk for recurrence in subgroups with prognostically favorable mutations. CONCLUSION GISTs with an identical KIT or PDGFRA mutation may have widely varying risks for recurrence. Most of the patients with PDGFRA mutations and those with KIT exon 11 duplication mutation or deletion of one codon have favorable RFS with surgery alone and are usually not candidates for adjuvant therapy.
Collapse
Affiliation(s)
- Heikki Joensuu
- Heikki Joensuu, Helsinki University Central Hospital, Helsinki, Finland; Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Toshirou Nishida, National Cancer Center Hospital East, Kashiwa, Japan; Sonja E. Steigen, University Hospital of North Norway and Tumor Biology Research Group, UiT The Arctic University of Norway, Tromsø, Norway; Peter Brabec, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic; Lukas Plank, Jessenius Medical Faculty of Comenius University and University Hospital, Martin; Jozef Sufliarsky, National Cancer Institute, Bratislava, Slovak Republic; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Chiara Braconi, Centro Regionale di Genetica Oncologica, Oncologia Medica, Ancona; Massimo Federico, University of Modena and Reggio Emilia, Modena, Italy; Chiara Braconi, The Institute of Cancer Research, Belmont, United Kingdom; Andrea Bordoni, Ticino Cancer Registry, Insitute of Pathology South of Switzerland, Locarno, Switzerland; Magnus K. Magnusson, University of Iceland; Jon G. Jonasson, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland; Isabelle Hostein, Bergonié Institute, Bordeaux; Pierre-Paul Bringier, E. Herriot Hospital, Lyon; Jean-Francois Emile, Versailles University and Assistance Publique-Hôpitaux de Paris, Ambroise Paré Hospital, Boulogne, France.
| | - Piotr Rutkowski
- Heikki Joensuu, Helsinki University Central Hospital, Helsinki, Finland; Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Toshirou Nishida, National Cancer Center Hospital East, Kashiwa, Japan; Sonja E. Steigen, University Hospital of North Norway and Tumor Biology Research Group, UiT The Arctic University of Norway, Tromsø, Norway; Peter Brabec, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic; Lukas Plank, Jessenius Medical Faculty of Comenius University and University Hospital, Martin; Jozef Sufliarsky, National Cancer Institute, Bratislava, Slovak Republic; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Chiara Braconi, Centro Regionale di Genetica Oncologica, Oncologia Medica, Ancona; Massimo Federico, University of Modena and Reggio Emilia, Modena, Italy; Chiara Braconi, The Institute of Cancer Research, Belmont, United Kingdom; Andrea Bordoni, Ticino Cancer Registry, Insitute of Pathology South of Switzerland, Locarno, Switzerland; Magnus K. Magnusson, University of Iceland; Jon G. Jonasson, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland; Isabelle Hostein, Bergonié Institute, Bordeaux; Pierre-Paul Bringier, E. Herriot Hospital, Lyon; Jean-Francois Emile, Versailles University and Assistance Publique-Hôpitaux de Paris, Ambroise Paré Hospital, Boulogne, France
| | - Toshirou Nishida
- Heikki Joensuu, Helsinki University Central Hospital, Helsinki, Finland; Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Toshirou Nishida, National Cancer Center Hospital East, Kashiwa, Japan; Sonja E. Steigen, University Hospital of North Norway and Tumor Biology Research Group, UiT The Arctic University of Norway, Tromsø, Norway; Peter Brabec, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic; Lukas Plank, Jessenius Medical Faculty of Comenius University and University Hospital, Martin; Jozef Sufliarsky, National Cancer Institute, Bratislava, Slovak Republic; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Chiara Braconi, Centro Regionale di Genetica Oncologica, Oncologia Medica, Ancona; Massimo Federico, University of Modena and Reggio Emilia, Modena, Italy; Chiara Braconi, The Institute of Cancer Research, Belmont, United Kingdom; Andrea Bordoni, Ticino Cancer Registry, Insitute of Pathology South of Switzerland, Locarno, Switzerland; Magnus K. Magnusson, University of Iceland; Jon G. Jonasson, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland; Isabelle Hostein, Bergonié Institute, Bordeaux; Pierre-Paul Bringier, E. Herriot Hospital, Lyon; Jean-Francois Emile, Versailles University and Assistance Publique-Hôpitaux de Paris, Ambroise Paré Hospital, Boulogne, France
| | - Sonja E Steigen
- Heikki Joensuu, Helsinki University Central Hospital, Helsinki, Finland; Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Toshirou Nishida, National Cancer Center Hospital East, Kashiwa, Japan; Sonja E. Steigen, University Hospital of North Norway and Tumor Biology Research Group, UiT The Arctic University of Norway, Tromsø, Norway; Peter Brabec, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic; Lukas Plank, Jessenius Medical Faculty of Comenius University and University Hospital, Martin; Jozef Sufliarsky, National Cancer Institute, Bratislava, Slovak Republic; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Chiara Braconi, Centro Regionale di Genetica Oncologica, Oncologia Medica, Ancona; Massimo Federico, University of Modena and Reggio Emilia, Modena, Italy; Chiara Braconi, The Institute of Cancer Research, Belmont, United Kingdom; Andrea Bordoni, Ticino Cancer Registry, Insitute of Pathology South of Switzerland, Locarno, Switzerland; Magnus K. Magnusson, University of Iceland; Jon G. Jonasson, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland; Isabelle Hostein, Bergonié Institute, Bordeaux; Pierre-Paul Bringier, E. Herriot Hospital, Lyon; Jean-Francois Emile, Versailles University and Assistance Publique-Hôpitaux de Paris, Ambroise Paré Hospital, Boulogne, France
| | - Peter Brabec
- Heikki Joensuu, Helsinki University Central Hospital, Helsinki, Finland; Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Toshirou Nishida, National Cancer Center Hospital East, Kashiwa, Japan; Sonja E. Steigen, University Hospital of North Norway and Tumor Biology Research Group, UiT The Arctic University of Norway, Tromsø, Norway; Peter Brabec, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic; Lukas Plank, Jessenius Medical Faculty of Comenius University and University Hospital, Martin; Jozef Sufliarsky, National Cancer Institute, Bratislava, Slovak Republic; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Chiara Braconi, Centro Regionale di Genetica Oncologica, Oncologia Medica, Ancona; Massimo Federico, University of Modena and Reggio Emilia, Modena, Italy; Chiara Braconi, The Institute of Cancer Research, Belmont, United Kingdom; Andrea Bordoni, Ticino Cancer Registry, Insitute of Pathology South of Switzerland, Locarno, Switzerland; Magnus K. Magnusson, University of Iceland; Jon G. Jonasson, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland; Isabelle Hostein, Bergonié Institute, Bordeaux; Pierre-Paul Bringier, E. Herriot Hospital, Lyon; Jean-Francois Emile, Versailles University and Assistance Publique-Hôpitaux de Paris, Ambroise Paré Hospital, Boulogne, France
| | - Lukas Plank
- Heikki Joensuu, Helsinki University Central Hospital, Helsinki, Finland; Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Toshirou Nishida, National Cancer Center Hospital East, Kashiwa, Japan; Sonja E. Steigen, University Hospital of North Norway and Tumor Biology Research Group, UiT The Arctic University of Norway, Tromsø, Norway; Peter Brabec, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic; Lukas Plank, Jessenius Medical Faculty of Comenius University and University Hospital, Martin; Jozef Sufliarsky, National Cancer Institute, Bratislava, Slovak Republic; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Chiara Braconi, Centro Regionale di Genetica Oncologica, Oncologia Medica, Ancona; Massimo Federico, University of Modena and Reggio Emilia, Modena, Italy; Chiara Braconi, The Institute of Cancer Research, Belmont, United Kingdom; Andrea Bordoni, Ticino Cancer Registry, Insitute of Pathology South of Switzerland, Locarno, Switzerland; Magnus K. Magnusson, University of Iceland; Jon G. Jonasson, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland; Isabelle Hostein, Bergonié Institute, Bordeaux; Pierre-Paul Bringier, E. Herriot Hospital, Lyon; Jean-Francois Emile, Versailles University and Assistance Publique-Hôpitaux de Paris, Ambroise Paré Hospital, Boulogne, France
| | - Bengt Nilsson
- Heikki Joensuu, Helsinki University Central Hospital, Helsinki, Finland; Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Toshirou Nishida, National Cancer Center Hospital East, Kashiwa, Japan; Sonja E. Steigen, University Hospital of North Norway and Tumor Biology Research Group, UiT The Arctic University of Norway, Tromsø, Norway; Peter Brabec, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic; Lukas Plank, Jessenius Medical Faculty of Comenius University and University Hospital, Martin; Jozef Sufliarsky, National Cancer Institute, Bratislava, Slovak Republic; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Chiara Braconi, Centro Regionale di Genetica Oncologica, Oncologia Medica, Ancona; Massimo Federico, University of Modena and Reggio Emilia, Modena, Italy; Chiara Braconi, The Institute of Cancer Research, Belmont, United Kingdom; Andrea Bordoni, Ticino Cancer Registry, Insitute of Pathology South of Switzerland, Locarno, Switzerland; Magnus K. Magnusson, University of Iceland; Jon G. Jonasson, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland; Isabelle Hostein, Bergonié Institute, Bordeaux; Pierre-Paul Bringier, E. Herriot Hospital, Lyon; Jean-Francois Emile, Versailles University and Assistance Publique-Hôpitaux de Paris, Ambroise Paré Hospital, Boulogne, France
| | - Chiara Braconi
- Heikki Joensuu, Helsinki University Central Hospital, Helsinki, Finland; Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Toshirou Nishida, National Cancer Center Hospital East, Kashiwa, Japan; Sonja E. Steigen, University Hospital of North Norway and Tumor Biology Research Group, UiT The Arctic University of Norway, Tromsø, Norway; Peter Brabec, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic; Lukas Plank, Jessenius Medical Faculty of Comenius University and University Hospital, Martin; Jozef Sufliarsky, National Cancer Institute, Bratislava, Slovak Republic; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Chiara Braconi, Centro Regionale di Genetica Oncologica, Oncologia Medica, Ancona; Massimo Federico, University of Modena and Reggio Emilia, Modena, Italy; Chiara Braconi, The Institute of Cancer Research, Belmont, United Kingdom; Andrea Bordoni, Ticino Cancer Registry, Insitute of Pathology South of Switzerland, Locarno, Switzerland; Magnus K. Magnusson, University of Iceland; Jon G. Jonasson, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland; Isabelle Hostein, Bergonié Institute, Bordeaux; Pierre-Paul Bringier, E. Herriot Hospital, Lyon; Jean-Francois Emile, Versailles University and Assistance Publique-Hôpitaux de Paris, Ambroise Paré Hospital, Boulogne, France
| | - Andrea Bordoni
- Heikki Joensuu, Helsinki University Central Hospital, Helsinki, Finland; Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Toshirou Nishida, National Cancer Center Hospital East, Kashiwa, Japan; Sonja E. Steigen, University Hospital of North Norway and Tumor Biology Research Group, UiT The Arctic University of Norway, Tromsø, Norway; Peter Brabec, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic; Lukas Plank, Jessenius Medical Faculty of Comenius University and University Hospital, Martin; Jozef Sufliarsky, National Cancer Institute, Bratislava, Slovak Republic; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Chiara Braconi, Centro Regionale di Genetica Oncologica, Oncologia Medica, Ancona; Massimo Federico, University of Modena and Reggio Emilia, Modena, Italy; Chiara Braconi, The Institute of Cancer Research, Belmont, United Kingdom; Andrea Bordoni, Ticino Cancer Registry, Insitute of Pathology South of Switzerland, Locarno, Switzerland; Magnus K. Magnusson, University of Iceland; Jon G. Jonasson, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland; Isabelle Hostein, Bergonié Institute, Bordeaux; Pierre-Paul Bringier, E. Herriot Hospital, Lyon; Jean-Francois Emile, Versailles University and Assistance Publique-Hôpitaux de Paris, Ambroise Paré Hospital, Boulogne, France
| | - Magnus K Magnusson
- Heikki Joensuu, Helsinki University Central Hospital, Helsinki, Finland; Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Toshirou Nishida, National Cancer Center Hospital East, Kashiwa, Japan; Sonja E. Steigen, University Hospital of North Norway and Tumor Biology Research Group, UiT The Arctic University of Norway, Tromsø, Norway; Peter Brabec, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic; Lukas Plank, Jessenius Medical Faculty of Comenius University and University Hospital, Martin; Jozef Sufliarsky, National Cancer Institute, Bratislava, Slovak Republic; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Chiara Braconi, Centro Regionale di Genetica Oncologica, Oncologia Medica, Ancona; Massimo Federico, University of Modena and Reggio Emilia, Modena, Italy; Chiara Braconi, The Institute of Cancer Research, Belmont, United Kingdom; Andrea Bordoni, Ticino Cancer Registry, Insitute of Pathology South of Switzerland, Locarno, Switzerland; Magnus K. Magnusson, University of Iceland; Jon G. Jonasson, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland; Isabelle Hostein, Bergonié Institute, Bordeaux; Pierre-Paul Bringier, E. Herriot Hospital, Lyon; Jean-Francois Emile, Versailles University and Assistance Publique-Hôpitaux de Paris, Ambroise Paré Hospital, Boulogne, France
| | - Jozef Sufliarsky
- Heikki Joensuu, Helsinki University Central Hospital, Helsinki, Finland; Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Toshirou Nishida, National Cancer Center Hospital East, Kashiwa, Japan; Sonja E. Steigen, University Hospital of North Norway and Tumor Biology Research Group, UiT The Arctic University of Norway, Tromsø, Norway; Peter Brabec, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic; Lukas Plank, Jessenius Medical Faculty of Comenius University and University Hospital, Martin; Jozef Sufliarsky, National Cancer Institute, Bratislava, Slovak Republic; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Chiara Braconi, Centro Regionale di Genetica Oncologica, Oncologia Medica, Ancona; Massimo Federico, University of Modena and Reggio Emilia, Modena, Italy; Chiara Braconi, The Institute of Cancer Research, Belmont, United Kingdom; Andrea Bordoni, Ticino Cancer Registry, Insitute of Pathology South of Switzerland, Locarno, Switzerland; Magnus K. Magnusson, University of Iceland; Jon G. Jonasson, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland; Isabelle Hostein, Bergonié Institute, Bordeaux; Pierre-Paul Bringier, E. Herriot Hospital, Lyon; Jean-Francois Emile, Versailles University and Assistance Publique-Hôpitaux de Paris, Ambroise Paré Hospital, Boulogne, France
| | - Massimo Federico
- Heikki Joensuu, Helsinki University Central Hospital, Helsinki, Finland; Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Toshirou Nishida, National Cancer Center Hospital East, Kashiwa, Japan; Sonja E. Steigen, University Hospital of North Norway and Tumor Biology Research Group, UiT The Arctic University of Norway, Tromsø, Norway; Peter Brabec, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic; Lukas Plank, Jessenius Medical Faculty of Comenius University and University Hospital, Martin; Jozef Sufliarsky, National Cancer Institute, Bratislava, Slovak Republic; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Chiara Braconi, Centro Regionale di Genetica Oncologica, Oncologia Medica, Ancona; Massimo Federico, University of Modena and Reggio Emilia, Modena, Italy; Chiara Braconi, The Institute of Cancer Research, Belmont, United Kingdom; Andrea Bordoni, Ticino Cancer Registry, Insitute of Pathology South of Switzerland, Locarno, Switzerland; Magnus K. Magnusson, University of Iceland; Jon G. Jonasson, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland; Isabelle Hostein, Bergonié Institute, Bordeaux; Pierre-Paul Bringier, E. Herriot Hospital, Lyon; Jean-Francois Emile, Versailles University and Assistance Publique-Hôpitaux de Paris, Ambroise Paré Hospital, Boulogne, France
| | - Jon G Jonasson
- Heikki Joensuu, Helsinki University Central Hospital, Helsinki, Finland; Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Toshirou Nishida, National Cancer Center Hospital East, Kashiwa, Japan; Sonja E. Steigen, University Hospital of North Norway and Tumor Biology Research Group, UiT The Arctic University of Norway, Tromsø, Norway; Peter Brabec, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic; Lukas Plank, Jessenius Medical Faculty of Comenius University and University Hospital, Martin; Jozef Sufliarsky, National Cancer Institute, Bratislava, Slovak Republic; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Chiara Braconi, Centro Regionale di Genetica Oncologica, Oncologia Medica, Ancona; Massimo Federico, University of Modena and Reggio Emilia, Modena, Italy; Chiara Braconi, The Institute of Cancer Research, Belmont, United Kingdom; Andrea Bordoni, Ticino Cancer Registry, Insitute of Pathology South of Switzerland, Locarno, Switzerland; Magnus K. Magnusson, University of Iceland; Jon G. Jonasson, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland; Isabelle Hostein, Bergonié Institute, Bordeaux; Pierre-Paul Bringier, E. Herriot Hospital, Lyon; Jean-Francois Emile, Versailles University and Assistance Publique-Hôpitaux de Paris, Ambroise Paré Hospital, Boulogne, France
| | - Isabelle Hostein
- Heikki Joensuu, Helsinki University Central Hospital, Helsinki, Finland; Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Toshirou Nishida, National Cancer Center Hospital East, Kashiwa, Japan; Sonja E. Steigen, University Hospital of North Norway and Tumor Biology Research Group, UiT The Arctic University of Norway, Tromsø, Norway; Peter Brabec, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic; Lukas Plank, Jessenius Medical Faculty of Comenius University and University Hospital, Martin; Jozef Sufliarsky, National Cancer Institute, Bratislava, Slovak Republic; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Chiara Braconi, Centro Regionale di Genetica Oncologica, Oncologia Medica, Ancona; Massimo Federico, University of Modena and Reggio Emilia, Modena, Italy; Chiara Braconi, The Institute of Cancer Research, Belmont, United Kingdom; Andrea Bordoni, Ticino Cancer Registry, Insitute of Pathology South of Switzerland, Locarno, Switzerland; Magnus K. Magnusson, University of Iceland; Jon G. Jonasson, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland; Isabelle Hostein, Bergonié Institute, Bordeaux; Pierre-Paul Bringier, E. Herriot Hospital, Lyon; Jean-Francois Emile, Versailles University and Assistance Publique-Hôpitaux de Paris, Ambroise Paré Hospital, Boulogne, France
| | - Pierre-Paul Bringuier
- Heikki Joensuu, Helsinki University Central Hospital, Helsinki, Finland; Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Toshirou Nishida, National Cancer Center Hospital East, Kashiwa, Japan; Sonja E. Steigen, University Hospital of North Norway and Tumor Biology Research Group, UiT The Arctic University of Norway, Tromsø, Norway; Peter Brabec, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic; Lukas Plank, Jessenius Medical Faculty of Comenius University and University Hospital, Martin; Jozef Sufliarsky, National Cancer Institute, Bratislava, Slovak Republic; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Chiara Braconi, Centro Regionale di Genetica Oncologica, Oncologia Medica, Ancona; Massimo Federico, University of Modena and Reggio Emilia, Modena, Italy; Chiara Braconi, The Institute of Cancer Research, Belmont, United Kingdom; Andrea Bordoni, Ticino Cancer Registry, Insitute of Pathology South of Switzerland, Locarno, Switzerland; Magnus K. Magnusson, University of Iceland; Jon G. Jonasson, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland; Isabelle Hostein, Bergonié Institute, Bordeaux; Pierre-Paul Bringier, E. Herriot Hospital, Lyon; Jean-Francois Emile, Versailles University and Assistance Publique-Hôpitaux de Paris, Ambroise Paré Hospital, Boulogne, France
| | - Jean-Francois Emile
- Heikki Joensuu, Helsinki University Central Hospital, Helsinki, Finland; Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Toshirou Nishida, National Cancer Center Hospital East, Kashiwa, Japan; Sonja E. Steigen, University Hospital of North Norway and Tumor Biology Research Group, UiT The Arctic University of Norway, Tromsø, Norway; Peter Brabec, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic; Lukas Plank, Jessenius Medical Faculty of Comenius University and University Hospital, Martin; Jozef Sufliarsky, National Cancer Institute, Bratislava, Slovak Republic; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Chiara Braconi, Centro Regionale di Genetica Oncologica, Oncologia Medica, Ancona; Massimo Federico, University of Modena and Reggio Emilia, Modena, Italy; Chiara Braconi, The Institute of Cancer Research, Belmont, United Kingdom; Andrea Bordoni, Ticino Cancer Registry, Insitute of Pathology South of Switzerland, Locarno, Switzerland; Magnus K. Magnusson, University of Iceland; Jon G. Jonasson, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland; Isabelle Hostein, Bergonié Institute, Bordeaux; Pierre-Paul Bringier, E. Herriot Hospital, Lyon; Jean-Francois Emile, Versailles University and Assistance Publique-Hôpitaux de Paris, Ambroise Paré Hospital, Boulogne, France
| |
Collapse
|